SIR 2019: VIRTUS subanalysis identifies correlates to improved patient outcomes after venous stenting

Mahmood Razavi (Orange, USA) reported new data, at SIR 2019, from a subanalysis of the VIRTUS trial, which set out to investigate the safety and efficacy of the Vici stent (Boston Scientific). The subanalysis forms part of the first prospective multicentre corelab adjudicated study that looked at correlates of clinical outcomes. It shed light on various baseline and procedural factors that are associated with clinical improvement as measured by Venous Clinical Severity Score (VCSS), one year after stenting. These included severity of patient symptoms before the procedure and lumen morphology after stent placement.

Razavi, Mahmood

Dr Mahmood Razavi (Los Angeles, USA) is one of the co-founders of Boston Scientific Santa Rosa Corp. (formerly Trivascular Inc). He is also the editor-in-chief of Techniques in Vascular & Interventional Radiology, and a member of the Council on Cardiovascular Radiology and Intervention – American Heart Association, as well as being an editorial board member of the Journal of Endovascular Specialists

Add comment

Editor’s Venous Pick

    Subscribeto receive the very best in medical videos